Sangamo Therapeutics (SGMO) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Join SI Premium – FREE
Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.26), $0.08 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $28 million versus the consensus estimate of $26.82 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SolarMax Technology (SMXT) Misses Q2 EPS by 98c
- UBS Reiterates Buy Rating on Chipotle Mexican Grill (CMG), Sees Likelihood of Starbucks Transaction as 'Somewhat Low'
- Barclays downgrades 2 software stocks ahead of Q3 earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
